ACU-4429: Phase I data

In a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial (4429-0001) in 18 healthy volunteers 55-80 years old, single oral doses of 2-20 mg ACU-4429 were well tolerated. There was an...